An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Trump Slams Iran Over Strait of Hormuz Oil Restrictions Amid Fragile Ceasefire
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
U.S. Inflation Surges in March as Iran War and Tariffs Drive Prices Higher
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Gold Prices Rise on Weaker Dollar and Ceasefire Hopes
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 



